Cargando…
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
BACKGROUND: There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes. OBJECTIVE: The aim of this study was to determine the association between MS and risks of adverse pregnancy and perinatal outcomes in women with MS. In women with M...
Autores principales: | Fink, Katharina, Gorczyca, Agnes, Alping, Peter, Englund, Simon, Farmand, Susan, Langer-Gould, Annette M, Piehl, Fredrik, McKay, Kyla, Frisell, Thomas, Razaz, Neda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176621/ https://www.ncbi.nlm.nih.gov/pubmed/37073483 http://dx.doi.org/10.1177/13524585231161492 |
Ejemplares similares
-
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020) -
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019) -
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021) -
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021) -
Risk of depression in multiple sclerosis across disease-modifying
therapies
por: Longinetti, Elisa, et al.
Publicado: (2021)